Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest treatment-resistant depression Stories

2013-10-24 23:32:21

One of the most advanced, non-invasive, researched and non-drug treatments for people living with chronic and treatment resistant depression is now in Austin, Texas. Texas TMS Center patients now have an opportunity to receive one of the most promising treatments for depression that is FDA-cleared, Brainsway® Deep TMS Therapy. Austin, Texas (PRWEB) October 24, 2013 Texas TMS Center, Austin, Texas, is proud to be one of the first in the United States to offer the breakthrough...

2013-07-01 20:21:14

LONDON, July 2, 2013 /PRNewswire/ -- Leading London Centre [http://www.psychiatrycentre.co.uk ] presents first 'real world' UK data, supporting effectiveness of repetitive Transcranial Magnetic Stimulation [http://www.psychiatrycentre.co.uk/our-services/repetitive-transcranial-magnetic-stimulation-rtms ] for the treatment of major depression Data from the first 'real-world' treatment audit presented today at The...

2013-05-01 08:32:04

Surveyed U.S. Psychiatrists Expect to Prescribe Edivoxetine to 25 Percent of Their Patients with Treatment-Resistant Depression, According to a New Report from Decision Resources BURLINGTON, Mass., May 1, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a greater effect on depressive symptoms than current treatments is one of the greatest unmet needs in patients with...

2013-04-17 20:21:28

LONDON, April 18, 2013 /PRNewswire/ -- 60% unaware of alternative depression treatments, other than taking pills Leading London Centre [http://www.psychiatrycentre.co.uk ] is the first and only to launch drug-free treatment for depression in UK Research launched today found that Britons value their mental wellness over their weight, sexual drive, fitness and gut health. According to results from a survey of 1,000 people in the UK, 77%...

2012-12-05 08:26:31

SAN DIEGO, Nov. 5, 2012 /PRNewswire/ -- BrainCells, Inc. (BCI), a leading biotechnology company developing novel compounds for the treatment of central nervous system (CNS) diseases, announced the successful completion of their Phase 1 multiple ascending dose (MAD) study of BCI-838, the oral prodrug for the company's Group II mGluR2/3 antagonist, BCI-632. BCI will advance the clinical development program of the compound by initiating a Proof-of-Concept (PoC) study in patients with...

2012-09-20 06:31:08

HOUSTON, Sept. 20, 2012 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX), a global leader in medical devices for the treatment and management of epilepsy, today announced an initial investment of EUR 2 million in cerbomed GmbH ("cerbomed"). Based in Erlangen, Germany, cerbomed is a privately-held company developing a non-invasive neurostimulation device for the treatment of epilepsy. The NEMOS(®) t-VNS device received CE Mark approval for the treatment of epilepsy and depression in 2010...

2012-05-23 02:26:51

HOUSTON, May 23, 2012 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ: CYBX) today announced that company co-founder, Reese S. Terry, Jr., is the recipient of the 2012 Professional Career Achievement Award from the Institute of Electrical and Electronic Engineers (IEEE) Engineering in Medicine & Biology Society. The award recognizes his significant contributions to therapeutic implantable devices and procedures for the treatment of epilepsy and drug-resistant chronic depression. Mr. Terry...

2011-12-09 06:30:00

RESEARCH TRIANGLE PARK, N.C., Dec. 9, 2011 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced completion of a $4.85 million financing. Existing investors Perseus Soros Biopharmaceutical Fund, L Capital Partners, Pappas Ventures and Omega Funds all participated in the financing. CeNeRx plans to use the proceeds to complete its ongoing Phase II trial of...

2011-06-22 06:30:00

EVANSTON, Ill., June 22, 2011 /PRNewswire/ -- Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has initiated a Phase II clinical trial of its lead compound GLYX-13. GLYX-13, a Glycine-site Functional Partial Agonist (GFPA) selective modulator of the NMDA receptor (NMDAR), is initially being developed as a therapy for patients who are not achieving an adequate response to their current...

2011-01-06 06:30:00

RESEARCH TRIANGLE PARK, N.C., Jan. 6, 2011 /PRNewswire/ -- CeNeRx BioPharma, Inc., today reported that it has initiated a Phase II trial of its new formulation of TriRima(TM), the company's novel antidepressant in development as monotherapy for treatment resistant depression. CeNeRx also announced that it will be presenting at Biotech Showcase(TM) 2011 on Tuesday, January 11, 2011 at 11:00 AM PST. TriRima is a member of a novel class of drugs known as RIMAs, or reversible and selective...